Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Merck Biopharma to Develop PharmaMar’s SCLC Drug in Japan
Merck Biopharma has obtained the exclusive rights to develop and commercialize Spain-based PharmaMar’s marine-derived drug lurbinectedin for the treatment of small cell lung cancer (SCLC) in Japan, the companies said on April 3. Under the deal, PharmaMar will receive an…
To read the full story
Related Article
- Merck Biopharma Files Lurbinectedin for SCLC in Japan
June 24, 2026
BUSINESS
- iPark Eyes Shared AI Platform to Keep Japan in Global Drug Discovery Race
July 14, 2026
- FDA Greenlights Leqembi Iqlik for Alzheimer’s Initiation Therapy
July 14, 2026
- Santen, Kyorin Strike Co-Promotion Deal for Alesion Eyelid Cream
July 14, 2026
- Takeda Commits Up to US$30 Million to Indonesia Plasma Partnership
July 14, 2026
- Padcev/Keytruda Bags Expanded US Nod in Perioperative MIBC
July 14, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…